OREX Financial Facts

Total other income (expense): -529K
Research and development: 15.47M
See Full Income Statement

Total liabilities and stockholders' equity: -121.49M
Cash and cash equivalents: -73.48M
See Full Balance Sheet

Orexigen Therapeutics (OREX) Earnings

  |   Expand Research on OREX
Next EPS Date 6/9/14 *Est. EPS Growth Rate +48.8% *Last Qtr.
Average EPS % Beat Rate -2.3% Revenue Growth Rate +99,900.0% *Last Qtr.
Average % Move 1-Wk after EPS +1.5% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. % Since Details
3/12/14 Q413 -$0.21-$0.19 -$0.02$857M$900M N/A -22.2% Details
11/12/13 Q313 -$0.19-$0.18 -$0.01$857K$800K N/A +5% Details
8/6/13 Q213 -$0.19-$0.19 $0.00N/A$900K N/A -28% Details
3/13/13 Q412 -$0.41-$0.44 +$0.03$857K$910K N/A -17.8% Details
11/7/12 Q312 -$0.44-$0.30 -$0.14$857K$890K N/A +16.5% Details
8/7/12 Q212 -$0.25-$0.17 -$0.08$857K$890K N/A +19.1% Details
5/9/12 Q112 -$0.16-$0.12 -$0.04$857K$900K N/A +47.6% Details
3/8/12 Q411 -$0.09-$0.10 +$0.01$857K$940K N/A +41.3% Details